Market CompetitionInvestor interest is focused on the potential FDA approval of RP1 in combination with Opdivo for the treatment of advanced melanoma, indicating competitive pressure.
Regulatory UncertaintyThe upcoming FDA decision on RP1’s BLA filing is seen as the next key catalyst for the stock, highlighting the potential for significant market impact.
Research And Development RisksRP2 is being developed in uveal melanoma and hepatocellular carcinoma, with new trials enrolling patients and expanding its research scope, which presents risks and uncertainties.